Intravenous Infusions (XGHA:IIL) Preferred Stock: GHS0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Preferred Stock?

Intravenous Infusions XGHA:IIL +8.86% Preferred Stock is GHS0.00 Mil as of . 20.

Preferred stock is a special equity security that has properties of both equity and debt. Intravenous Infusions's preferred stock for the quarter that ended in . 20 was GHS0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Intravenous Infusions's Enterprise Value for the quarter that ended in . 20 was GHS0.00 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Intravenous Infusions's Book Value per Share for the quarter that ended in . 20 was GHS.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Intravenous Infusions's Earnings per Share (Diluted) for the six months ended in . 20 was GHS.


Intravenous Infusions  (XGHA:IIL) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Intravenous Infusions's Enterprise Value for the quarter that ended in . 20 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Intravenous Infusions's Book Value per Share for the quarter that ended in . 20 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Intravenous Infusions's Earnings per Share (Diluted) (EPS) for the six months ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intravenous Infusions Preferred Stock Related Terms


Intravenous Infusions Preferred Stock Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Preferred Stock Chart

Intravenous Infusions Annual Data
Trend
Preferred Stock

Intravenous Infusions Semi-Annual Data
Preferred Stock

Intravenous Infusions Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.

Frequently Asked Questions Learn more about Preferred Stock →
What does a Preferred Stock of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Preferred Stock of GHS0.00 Mil as of . 20. Preferred Stock represents the par value of a company's preferred shares. View historical data on Intravenous Infusions and its competitors.
Is Intravenous Infusions' Preferred Stock too high?
Intravenous Infusions' current Preferred Stock is GHS0.00 Mil.
How does Intravenous Infusions' Preferred Stock compare to PTLF and PCYN?
Intravenous Infusions' Preferred Stock of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Preferred Stock for a Drug Manufacturers company?
A good Preferred Stock depends on the Drug Manufacturers industry context. However, Preferred Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Preferred Stock mean?
A high Preferred Stock can signal that a stock is expensive relative to its fundamentals. Preferred Stock represents the par value of a company's preferred shares. View historical data on Intravenous Infusions and its competitors. Intravenous Infusions's current Preferred Stock is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Preferred Stock of GHS0.00 Mil. The current Preferred Stock is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Preferred Stock calculated?
Preferred Stock is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Preferred Stock is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.